Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 932-124-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- other: Clinical case
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: A well documented case study
Data source
Reference
- Reference Type:
- publication
- Title:
- Calcium Carbonate Consumption During Pregnancy: An Unusual Cause of Neonatal Hypocalcemia
- Author:
- Robertson WC
- Year:
- 2 002
- Bibliographic source:
- J Child Neurol, 17: 853-855
Materials and methods
- Study type:
- clinical case study
- Endpoint addressed:
- developmental toxicity / teratogenicity
Test guideline
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- The paper reports a clinical case of neonatal hypocalcaemia possibly caused by the maternal ingestion of antacids.
- GLP compliance:
- no
Test material
- Reference substance name:
- Tums EX tablet containing 750 mg calcium carbonate
- IUPAC Name:
- Tums EX tablet containing 750 mg calcium carbonate
- Details on test material:
- - Name of test material: Tums EX tablet each containing 750 mg calcium carbonate
Constituent 1
Method
- Subjects:
- The mother was a healthy 24 year old who developed significant acid indigestion early in pregnancy and treated the dyspepsia by taking 10 to 14 extra strength Tums daily. The calcium carbonate was started midway through the first trimester and continued until the onset of labour.
The child was delivered at 39 weeks of gestation, appeared healthy and was sent home on the second day of life. During the first week of life the infant was active, alert and fed without difficulty.
At 8 days old the previously healthy infant was evaluated following five 30 second episodes of jerking movements of all limbs. - Route of exposure:
- other: via the mother during pregnancy
- Reason of exposure:
- intentional
- Exposure assessment:
- estimated
Results and discussion
- Clinical signs:
- Examination revealed an active, healthy appearing 3.6 kg male infant with mild icterus. General physical examination and neurologic assessment were appropriate for age. Carpopedal spasm, Chvostek's sign and stridor were not present.
Admission laboratory values were normal except for a total calcium of 6.3 mg/dL. Blood glucose was 82 mg/dL and cerebrospinal fluid studies were unremarkable. Initial haematological studies did not include serum phosphorus.
There were three additional spells of generalised clonic activity lasting approximately 30 seconds during the first 10 hours of hospitalisation. There was no subsequent seizure activity. - Results of examinations:
- Brain magnetic resonance imaging was normal except for probable decreased flow through the right transverse sinus. An EEG contained frequent temporal and occipital spike discharges.
Serologic tests for hypercoagulability were negative and chest radiographs revealed a typical thymic shadow. Liver function studies were normal except for a total bilirubin of 12.1 mg/dL. Serum pH, magnesium levels, total protein and creatinine were unremarkable. Free thyroxine, 1,25-dihydroxyvitamin D and parathormone values were also normal. - Effectivity of medical treatment:
- The child received 20 mg/kg of iv phenobarbital shortly after admission and 180 mg of intravenous calcium gluconate soon after the laboratory reported his serum calcium. Three additional doses of 360 mg of calcium gluconate were given 6 hours apart during the first day of hospitalisation.
The infant received a single intravenous dose of 360 mg of calcium gluconate on the second hospital day. - Outcome of incidence:
- The child's ionised calcium gradually improved and his serum phosphorus levels slowly decreased to near normal values. After 6 days of hospitalisation, the child's total calcium was 8.8 mg/dL and haemoglobin and haematocrit were 14.3 g/L and 41.3%, respectively. He was discharged at 2 weeks of age on phenobarbital, calcium carbonate and low-phosphate formula.
After discharge, the infant was gradually removed from calcium supplementation and placed on regular formula by 9 weeks of age. Calcium and phosphorus levels remained normal and there was no additional seizure activity. Evaluation at 3 months of age revealed a healthy child with no abnormalities on physical examination. Follow-up EEG was normal and the infant was weaned from phenobarbital without incident.
Applicant's summary and conclusion
- Conclusions:
- The paper reports the clinical case of a child whose mother took large doses of calcium carbonate throughout pregnancy. The infant developed seizures on the 8th day of life which appeared to be secondary to hypocalcaemia. Obvious causes for hypocalcaemia were excluded. Our observations suggest that maternal ingestion of excessive amounts of calcium may temporarily suppress neonatal parathormone production causing late neonatal hypocalcaemia.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.